Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28073
Title: The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma.
Austin Authors: Arulananda, Surein;Lee, Erinna F;Fairlie, Walter Douglas ;John, Thomas 
Affiliation: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
School of Cancer Medicine, La Trobe University, Heidelberg, Australia
Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Victoria, Australia
Medical Oncology
Olivia Newton-John Cancer Research Institute
Issue Date: Apr-2021
metadata.dc.date: 2020-12-10
Publication information: Expert Review of Anticancer Therapy 2021; 21(4): 413-424
Abstract: Introduction: With limited recent therapeutic changes, malignant pleural mesothelioma (MPM) is associated with poor survival and death within 12 months, making it one of the most lethal malignancies. Due to unregulated asbestos use in developing countries and home renovation exposures, cases of MPM are likely to present for decades. As MPM is largely driven by dysregulation of tumor suppressor genes, researchers have examined other mechanisms of subverting tumor proliferation and spread. Over-expression of pro-survival BCL-2 family proteins impairs cells from undergoing apoptosis, and BH3-mimetics  targeting them are a novel treatment option across various cancers, though have not been widely investigated in MPM.Areas covered: This review provides an overview of MPM and its current treatment landscape. It summarizes the role of BCL-2 family proteins in tumorigenesis and the therapeutic potential of BH3-mimetics . Finally, it discusses the role of BCL-2 proteins in MPM and the pre-clinical rationale for investigating BH3-mimetics as a therapeutic strategy.Expert opinion: As a disease without readily actionable oncogene driver mutations and with modest benefit from immune checkpoint inhibition, novel therapeutic options are urgently needed for MPM. Hence, BH3-mimetics provide a promising treatment option, with evidence supporting dependence on pro-survival BCL-2 proteins for MPM cell survival.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28073
DOI: 10.1080/14737140.2021.1856660
PubMed URL: 33238762
Type: Journal Article
Subjects: Apoptosis
BCL-2 family proteins
BH3-mimetics
cell death
malignant pleural mesothelioma
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.